Literature DB >> 17724286

Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia.

F Binkofski1, K Reetz, C Gaser, R Hilker, J Hagenah, K Hedrich, T van Eimeren, A Thiel, C Büchel, P P Pramstaller, H R Siebner, C Klein.   

Abstract

BACKGROUND: Mutations in the Parkin and PINK1 genes can cause parkinsonism. Since asymptomatic carriers of a single mutant allele of the Parkin or PINK1 gene display a presynaptic dopaminergic dysfunction in the striatum, they provide a unique in vivo model to study structural and functional reorganization in response to latent nigrostriatal dysfunction. We hypothesized that subclinical nigrostriatal neurodegeneration caused by these mutations would induce morphologic changes in the dysfunctional striatal gray matter.
METHODS: In asymptomatic carriers of a heterozygous Parkin (n = 13) or PINK1 (n = 10) mutation and 23 age-and sex-matched individuals without a mutation, we applied observer independent region-of-interest and voxel-based morphometry to high-resolution structural MRIs.
RESULTS: Relative to controls without a mutation, Parkin and PINK1 mutation carriers displayed a bilateral increase in gray matter volume in the putamen and the internal globus pallidus. In 8 of the 13 Parkin mutation carriers, the presynaptic dopaminergic function was studied with (18)F-DOPA PET. The metabolic-morphometric regression analysis revealed that the linear decrease in individual presynaptic striatal (18)F-DOPA uptake was linked to a reciprocal decrease in the striatal gray matter volume in the putamen bilaterally and in the left caudate nucleus.
CONCLUSIONS: The alternative causes of the increased striatal gray matter volume may be either due to excessive levels of neuronal activity caused by chronic dopaminergic dysfunction or due to long-term adaptation to chronic nigrostriatal dysfunction actively compensating for the dopaminergic denervation. In any case, the results indicate that a genetically driven regional dysfunction may be imprinted in the structure of the dysfunctional brain region, for example in the striatum.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17724286     DOI: 10.1212/01.wnl.0000267844.72421.6c

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  20 in total

1.  The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study.

Authors:  Madeleine E Sharp; Elise Caccappolo; Helen Mejia-Santana; Ming-X Tang; Llency Rosado; Martha Orbe Reilly; Diana Ruiz; Elan D Louis; Cynthia Comella; Martha Nance; Susan Bressman; William K Scott; Caroline Tanner; Cheryl Waters; Stanley Fahn; Lucien Cote; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Haydeh Payami; Eric Molho; Stuart A Factor; John Nutt; Carmen Serrano; Maritza Arroyo; Michael W Pauciulo; William C Nichols; Lorraine N Clark; Roy N Alcalay; Karen S Marder
Journal:  Mov Disord       Date:  2014-11-12       Impact factor: 10.338

2.  Genetics of Parkinson disease.

Authors:  E Ben-David; R Tu
Journal:  AJNR Am J Neuroradiol       Date:  2014-09-04       Impact factor: 3.825

Review 3.  Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes.

Authors:  Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2011-01-05       Impact factor: 3.575

4.  Longitudinal Study of Gray Matter Changes in Parkinson Disease.

Authors:  X Jia; P Liang; Y Li; L Shi; D Wang; K Li
Journal:  AJNR Am J Neuroradiol       Date:  2015-09-10       Impact factor: 3.825

Review 5.  [Imaging of genetic aspects of Parkinson's disease].

Authors:  N Brüggemann; J Vegt; C Klein; H R Siebner
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

6.  Enhanced sensitivity to group II mGlu receptor activation at corticostriatal synapses in mice lacking the familial parkinsonism-linked genes PINK1 or Parkin.

Authors:  G Martella; P Platania; D Vita; G Sciamanna; D Cuomo; A Tassone; A Tscherter; T Kitada; P Bonsi; J Shen; A Pisani
Journal:  Exp Neurol       Date:  2008-11-21       Impact factor: 5.330

7.  Parkin and PINK1 mutations in early-onset Parkinson's disease: comprehensive screening in publicly available cases and control.

Authors:  J Brooks; J Ding; J Simon-Sanchez; C Paisan-Ruiz; A B Singleton; S W Scholz
Journal:  J Med Genet       Date:  2009-04-06       Impact factor: 6.318

8.  Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.

Authors:  Xiao-Hong Lu; Sheila M Fleming; Bernhard Meurers; Larry C Ackerson; Farzad Mortazavi; Victor Lo; Daniela Hernandez; David Sulzer; George R Jackson; Nigel T Maidment; Marie-Francoise Chesselet; X William Yang
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

9.  Putaminal volume and diffusion in early familial Creutzfeldt-Jakob disease.

Authors:  Ilana Seror; Hedok Lee; Oren S Cohen; Chen Hoffmann; Isak Prohovnik
Journal:  J Neurol Sci       Date:  2009-10-13       Impact factor: 3.181

10.  Heterozygous carriers of a Parkin or PINK1 mutation share a common functional endophenotype.

Authors:  B F L van Nuenen; M M Weiss; B R Bloem; K Reetz; T van Eimeren; K Lohmann; J Hagenah; P P Pramstaller; F Binkofski; C Klein; H R Siebner
Journal:  Neurology       Date:  2008-11-26       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.